ALPN-303
Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m
The deal focuses on T cell-based therapies for autoimmune disease
Novartis’ ianalumab shows promise in phase 3 Sjögren’s syndrome studies
The systemic autoimmune disease affects approximately 0.6% of the UK’s adult population
AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata
Around 700,000 people in the US are living with some form of the autoimmune disease
BMS and Bain Capital launch new company to develop immunology therapies
The newly formed company has in-licensed five investigational immunology drugs from BMS
Novartis and Matchpoint enter inflammatory disease partnership worth $1bn
The companies will focus on inflammatory diseases that have been historically difficult to treat
AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn
ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma
Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE
The rare inherited disease affects approximately 11,000 people in the UK
Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval
The rare inherited disease affects more than 109,000 people worldwide
Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m
The B cell depletion therapy has the potential to reach patients earlier in their treatment journeys
AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis
The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population
Pfizer and Flagship Pioneering enter autoimmune disease partnership
More than 100 known types of autoimmune diseases affect over 50 million people in the US
Sanofi expands immunology pipeline by acquiring Dren’s bispecific for $600m upfront
The candidate has shown potential in treating B-cell mediated autoimmune diseases